Amendment No. 10 to Subaward Agreement between Yale University and Miragen Therapeutics, Inc.

Contract Categories: Business Finance › Modification Agreements
Summary

Yale University and Miragen Therapeutics, Inc. have amended their subaward agreement related to the NIH-funded project on Mir-29 mimicry as a therapy for pulmonary fibrosis. This amendment extends the project period through June 30, 2021, and authorizes additional funding and carryover as specified. All other terms of the original agreement remain unchanged. The amendment is signed by authorized representatives of both parties.

Read More Arrow
EX-10.1 2 mgen-q32020xex101yale.htm EX-10.1 Document
Exhibit 10.1
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK, “[*]”.
FDP Amendment
Number
10
Pass-Through Entity (PTE)
Subrecipient
Yale University
Entity Name
Miragen Therapeutics, Inc.
gcat5@yale.edu
Email Address
jleverone@miragenrx.com
[*], MD
Principal Investigator
Rusty Montgomery, MD
Project Title:
Mir-29 mimicry as a therapy for pulmonary fibrosis
  PTE Federal Award No:
  Federal Awarding Agency:
5UH3HL123886-05 REVISED
National Institutes of Health (NIH)
Revised Period of Performance:
  Amount Funded This Action:
Subaward No:
Start Date:
September 1, 2018
End Date:
Jun 30, 2021
$ [*]
GR1004495 (CON-80001453)
Total Amount of Federal Funds Obligated to Date:
Cost Share:Subject to FFATA:
Automatic Carryover:
$ [*]
☐
Yes☒No
☐
Yes☒No
☐
Yes☒No
Amendment(s) to Original Terms and Conditions
This Amendment revises the above-referenced Subaward Agreement as follows:
üThis is a [*] Extension. The Period of Performance is hereby extended through:06/30/2021
tois hereby added to the Period of Performance, which is revised to be consistent with the Period of Performance Start and End Date above.
Additional funds in the amount ofare hereby authorized for the current period.
Carryover in the amount of is hereby authorized as shown below.
Other (see below)
For clarity: all amounts stated in this amendment are in United States Dollars.
All other terms and conditions of this Subaward Agreement remain in full force and effect.
By an Authorized Official of PTE:
By an Authorized Official of Subrecipient:
/s/ Lindsey Bosak
Aug 20, 2020
/s/ Jason A. Leverone
Aug 11, 2020
Name:
Lindsey Bosak
Date
Name:
Jason A. Leverone
Date
Title:
Award Manager, SO/AOR
Title:
CFO